IPCALAB Stock Overview
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for IPCALAB from our risk checks.
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,347.25 |
| 52 Week High | ₹1,374.60 |
| 52 Week Low | ₹669.80 |
| Beta | 0.23 |
| 1 Month Change | 12.64% |
| 3 Month Change | 20.78% |
| 1 Year Change | 92.08% |
| 3 Year Change | 31.73% |
| 5 Year Change | 182.89% |
| Change since IPO | 3,445.39% |
Recent News & Updates
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07
Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Recent updates
Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Mar 15These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well
Sep 20Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Aug 09Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Jun 08How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?
Mar 26Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?
Mar 13Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently
Feb 28Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 23Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?
Feb 11Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?
Jan 30The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It
Jan 15Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Dec 31
Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Dec 16The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?
Dec 13This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)
Nov 28Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Nov 25Ipca Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Nov 10Is Ipca Laboratories Limited's (NSE:IPCALAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Nov 08Do Insiders Own Lots Of Shares In Ipca Laboratories Limited (NSE:IPCALAB)?
Oct 24Ipca Laboratories' (NSE:IPCALAB) Wonderful 327% Share Price Increase Shows How Capitalism Can Build Wealth
Oct 09What We Learned About Ipca Laboratories' (NSE:IPCALAB) CEO Compensation
Sep 24Shareholder Returns
| IPCALAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.4% | -0.1% | 1.8% |
| 1Y | 92.1% | 55.9% | 46.4% |
Return vs Industry: IPCALAB exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: IPCALAB exceeded the Indian Market which returned 46.1% over the past year.
Price Volatility
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: IPCALAB has not had significant price volatility in the past 3 months.
Volatility Over Time: IPCALAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 16,167 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives.
Ipca Laboratories Limited Fundamentals Summary
| IPCALAB fundamental statistics | |
|---|---|
| Market cap | ₹341.80b |
| Earnings (TTM) | ₹5.64b |
| Revenue (TTM) | ₹71.87b |
60.6x
P/E Ratio4.8x
P/S RatioIs IPCALAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCALAB income statement (TTM) | |
|---|---|
| Revenue | ₹71.87b |
| Cost of Revenue | ₹26.97b |
| Gross Profit | ₹44.90b |
| Other Expenses | ₹39.26b |
| Earnings | ₹5.64b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.24 |
| Gross Margin | 62.47% |
| Net Profit Margin | 7.85% |
| Debt/Equity Ratio | 26.3% |
How did IPCALAB perform over the long term?
See historical performance and comparison